ANGIOTENSIN II IN REFRACTORY SEPTIC SHOCK

被引:50
作者
Antonucci, Elio [1 ]
Gleeson, Patrick J. [2 ]
Annoni, Filippo [2 ]
Agosta, Sara [1 ]
Orlando, Sergio [1 ]
Taccone, Fabio Silvio [2 ]
Velissaris, Dimitrios [3 ]
Scolletta, Sabino [4 ,5 ]
机构
[1] Guglielmo da Saliceto Hosp, Emergency Dept, Intermediate Care Unit, Via Taverna 49, I-29121 Piacenza, Italy
[2] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Intens Care, Brussels, Belgium
[3] Univ Hosp Patras, Dept Internal Med, Rion, Greece
[4] Univ Siena, Dept Med Biotechnol, Siena, Italy
[5] Siena Univ Hosp, Cardiothorac Anesthesia & Intens Care Unit, Siena, Italy
来源
SHOCK | 2017年 / 47卷 / 05期
关键词
Circulatory failure; hemodynamic stabilization; organ dysfunction; sepsis; vasopressors; RECEPTOR-ASSOCIATED PROTEIN; ALDOSTERONE SYSTEM; DOWN-REGULATION; RENIN; SEPSIS; INFLAMMATION; INJURY;
D O I
10.1097/SHK.0000000000000807
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Refractory septic shock is defined as persistently low mean arterial blood pressure despite volume resuscitation and titrated vasopressors/inotropes in patients with a proven or suspected infection and concomitant organ dysfunction. Its management typically requires high doses of catecholamines, which can induce significant adverse effects such as ischemia and arrhythmias. Angiotensin II (Ang II), a key product of the renin-angiotensin-aldosterone system, is a vasopressor agent that could be used in conjunction with other vasopressors to stabilize critically ill patients during refractory septic shock, and reduce catecholamine requirements. However, very few clinical data are available to support Ang II administration in this setting. Here, we review the current literature on this topic to better understand the role of Ang II administration during refractory septic shock, differentiating experimental from clinical studies. We also consider the potential role of exogenous Ang II administration in specific organ dysfunction and possible pitfalls with Ang II in sepsis. Various issues remain unresolved and future studies should investigate important topics such as: the optimal dose and timing of Ang II administration, a comparison between Ang II and the other vasopressors (epinephrine; vasopressin), and Ang II effects on microcirculation.
引用
收藏
页码:560 / 566
页数:7
相关论文
共 55 条
[1]   Myocardial depression in sepsis: From pathogenesis to clinical manifestations and treatment [J].
Antonucci, Elio ;
Fiaccadori, Enrico ;
Donadello, Katia ;
Taccone, Fabio Silvio ;
Franchi, Federico ;
Scolletta, Sabino .
JOURNAL OF CRITICAL CARE, 2014, 29 (04) :500-511
[2]   High versus Low Blood-Pressure Target in Patients with Septic Shock [J].
Asfar, Pierre ;
Meziani, Ferhat ;
Hamel, Jean-Francois ;
Grelon, Fabien ;
Megarbane, Bruno ;
Anguel, Nadia ;
Mira, Jean-Paul ;
Dequin, Pierre-Francois ;
Gergaud, Soizic ;
Weiss, Nicolas ;
Legay, Francois ;
Le Tulzo, Yves ;
Conrad, Marie ;
Robert, Rene ;
Gonzalez, Frederic ;
Guitton, Christophe ;
Tamion, Fabienne ;
Tonnelier, Jean-Marie ;
Guezennec, Pierre ;
Van der Linden, Thierry ;
Vieillard-Baron, Antoine ;
Mariotte, Eric ;
Pradel, Gael ;
Lesieur, Olivier ;
Ricard, Jean-Damien ;
Herve, Fabien ;
du Cheyron, Damien ;
Guerin, Claude ;
Mercat, Alain ;
Teboul, Jean-Louis ;
Radermacher, Peter .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (17) :1583-1593
[3]   Angiotensin II-triggered kinase signaling cascade in the central nervous system [J].
Bali, Anjana ;
Jaggi, Amteshwar Singh .
REVIEWS IN THE NEUROSCIENCES, 2016, 27 (03) :301-315
[4]   Angiotensin II revisited: new roles in inflammation, immunology and aging [J].
Benigni, Ariela ;
Cassis, Paola ;
Remuzzi, Giuseppe .
EMBO MOLECULAR MEDICINE, 2010, 2 (07) :247-257
[5]   A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme [J].
Bernstein, Kenneth E. ;
Ong, Frank S. ;
Blackwell, Wendell-Lamar B. ;
Shah, Kandarp H. ;
Giani, Jorge F. ;
Gonzalez-Villalobos, Romer A. ;
Shen, Xiao Z. ;
Fuchs, Sebastien .
PHARMACOLOGICAL REVIEWS, 2013, 65 (01) :1-46
[6]   Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis [J].
Bucher, M ;
Hobbhahn, J ;
Kurtz, A .
CRITICAL CARE MEDICINE, 2001, 29 (09) :1750-1755
[7]   Downregulation of angiotensin II type I receptors during sepsis [J].
Bucher, M ;
Ittner, KP ;
Hobbhahn, J ;
Taeger, K ;
Kurtz, A .
HYPERTENSION, 2001, 38 (02) :177-182
[8]   Glomerular haemodynamics, the renal sympathetic nervous system and sepsis-induced acute kidney injury [J].
Calzavacca, Paolo ;
May, Clive N. ;
Bellomo, Rinaldo .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (12) :2178-2184
[9]   Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study [J].
Chawla, Lakhmir S. ;
Busse, Laurence ;
Brasha-Mitchell, Ermira ;
Davison, Danielle ;
Honiq, Jacqueline ;
Alotaibi, Ziyad ;
Seneff, Michael G. .
CRITICAL CARE, 2014, 18 (05)
[10]   Sepsis: a roadmap for future research [J].
Cohen, Jonathan ;
Vincent, Jean-Louis ;
Adhikari, Neill K. J. ;
Machado, Flavia R. ;
Angus, Derek C. ;
Calandra, Thierry ;
Jaton, Katia ;
Giulieri, Stefano ;
Delaloye, Julie ;
Opal, Steven ;
Tracey, Kevin ;
van der Poll, Tom ;
Pelfrene, Eric .
LANCET INFECTIOUS DISEASES, 2015, 15 (05) :581-614